MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Geri Gentry on Oct 7th, 2026

Shares of MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $24.71.

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of MeiraGTx in a report on Wednesday, July 8th. The Goldman Sachs Group started coverage on MeiraGTx in a report on Thursday, September 24th. They set a “neutral” rating and a $16.00 price target on the stock. Weiss Ratings raised MeiraGTx from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Wall Street Zen cut MeiraGTx from a “buy” rating to a “hold” rating in a report on Saturday, September 26th. Finally, Zacks Research lowered MeiraGTx from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 11th.

Check Out Our Latest Research Report on MGTX

Insider Buying and Selling

In related news, CFO Richard Giroux sold 56,000 shares of the firm’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $12.51, for a total value of $700,560.00. Following the completion of the sale, the chief financial officer owned 908,530 shares of the company’s stock, valued at $11,365,710.30. This trade represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of MeiraGTx stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $10.64, for a total transaction of $294,291.76. Following the completion of the sale, the insider owned 613,187 shares in the company, valued at approximately $6,524,309.68. This trade represents a 4.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 145,659 shares of company stock valued at $1,854,172 over the last quarter. 7.40% of the stock is owned by company insiders.

Institutional Trading of MeiraGTx

Hedge funds and other institutional investors have recently modified their holdings of the business. ProShare Advisors LLC bought a new position in MeiraGTx during the 4th quarter valued at approximately $94,000. Bank of Nova Scotia purchased a new stake in shares of MeiraGTx in the first quarter worth $105,000. Algert Global LLC increased its holdings in shares of MeiraGTx by 13.9% during the second quarter. Algert Global LLC now owns 11,700 shares of the company’s stock valued at $158,000 after acquiring an additional 1,430 shares in the last quarter. Perigon Wealth Management LLC bought a new position in shares of MeiraGTx during the second quarter valued at $203,000. Finally, Arizona State Retirement System purchased a new position in shares of MeiraGTx in the 2nd quarter worth about $207,000. 67.48% of the stock is owned by hedge funds and other institutional investors.

MeiraGTx Price Performance

MGTX opened at $10.60 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.76 and a quick ratio of 3.76. The stock’s 50 day simple moving average is $12.87 and its 200 day simple moving average is $11.24. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of 14.93 and a beta of 1.35. MeiraGTx has a 1 year low of $6.62 and a 1 year high of $15.35.

MeiraGTx (NASDAQ:MGTX – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $2.17. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%.The firm had revenue of $321.43 million during the quarter, compared to analyst estimates of $0.70 million. As a group, analysts predict that MeiraGTx will post 0.3 earnings per share for the current year.

MeiraGTx Company Profile

(Get Free Report)

MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage biotechnology company developing gene therapy and ribonucleic acid (RNA) medicines for diseases with significant unmet medical needs. Its research focuses primarily on the central nervous system, immune-mediated conditions and disorders affecting salivary gland function.

The company’s technology platforms are designed to deliver therapeutic genes or regulate gene expression in targeted tissues. Its investigational programs have included gene therapies for Parkinson’s disease and radiation-induced xerostomia, a condition involving chronic dry mouth after cancer treatment.